A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 15, 2012

Primary Completion Date

November 16, 2012

Study Completion Date

November 16, 2012

Conditions

Asthma

Interventions

DRUG

FF, 50 mcg

Novel dry powder inhaler

DRUG

FF, 100 mcg

Novel dry powder inhaler

DRUG

FF, 200 mcg

Novel dry powder inhaler

DRUG

FF, 250 mcg

Intravenous

Trial Locations (1)

GSK Investigational Site, Groningen